Tob negatively regulates NF-κB activation in breast cancer through its association with the TNF receptor complex

Area of Science:

• Molecular Biology
• Cancer Research
• Immunology

Background:

• Nuclear factor-kappa B (NF-κB) signaling is vital for biological functions but its overactivation contributes to autoimmune diseases, inflammation, and cancer.
• Aggressive breast cancers often lack specific molecular targets, necessitating research into NF-κB signaling pathways for improved therapeutic strategies.

Purpose of the Study:

• To investigate the role of Tob, an antiproliferative protein, as a regulator of NF-κB signaling in breast cancer.
• To explore the therapeutic potential of targeting Tob-mediated regulation of NF-κB in breast cancer treatment.

Main Methods:

• Analysis of Tob expression and NF-κB activity across 35 human breast cancer cell lines.
• Examination of The Cancer Genome Atlas (TCGA) database for correlations between Tob expression and NF-κB activity in clinical samples.
• Functional studies involving Tob knockdown and overexpression in breast cancer cells to assess NF-κB activation upon TNF-α stimulation.
• Investigation of the molecular mechanism involving Tob's interaction with the TNF receptor complex and RIPK1 polyubiquitylation.

Main Results:

• Tob expression was found to be negatively correlated with NF-κB activity in breast cancer cell lines and clinical samples.
• Tob knockdown led to NF-κB overactivation, while Tob overexpression inhibited TNF-α-induced NF-κB activation.
• Mechanistically, Tob was shown to associate with the TNF receptor complex and inhibit RIPK1 polyubiquitylation, a key step in NF-κB activation.

Conclusions:

• Tob functions as a negative regulator of NF-κB signaling in breast cancer.
• The findings suggest Tob as a potential therapeutic target for managing NF-κB-driven breast cancers.
• Understanding Tob's role in inhibiting NF-κB activation provides insights into novel therapeutic strategies for aggressive breast cancer.